N
Nektar Therapeutics (NKTR)
NCM – Real Time Price. Currency in USD
68.66
-2.31 (-3.25%)
At close: Mar 27, 2026, 4:00 PM EDT
69.40
+0.74 (1.08%)
After-hours: Mar 27, 2026, 7:15 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
68.66
-2.31 (-3.25%)
At close: Mar 27, 2026, 4:00 PM EDT
69.40
+0.74 (1.08%)
After-hours: Mar 27, 2026, 7:15 PM EDT
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Name | Position |
|---|---|
| Dr. Jonathan Zalevsky Ph.D. | Senior VP and Chief Research & Development Officer |
| Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development & Manufacturing |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
| Mr. Howard W. Robin | CEO, President & Director |
| Mr. Jason Barnard | Chief Accounting Officer |
| Mr. Robert Bacci | Chief People Officer and Head of Quality & Facilities |
| Ms. Charleen Jue | Senior Vice President of Clinical Development Operations |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 10-K | nktr-20251231.htm |
| 2026-03-12 | 8-K | ea0281334-8k_nektar.htm |
| 2026-01-27 | 8-K | ea0274309-8k_nektar.htm |
| 2025-12-16 | 8-K | d24251d8k.htm |
| 2025-11-21 | 8-K | ea0266707-8k_nektar.htm |
| 2025-11-10 | 8-K | ea0264736-8k_nektar.htm |
| 2025-11-07 | 10-Q | nktr-20250930.htm |
| 2025-11-06 | 8-K | ea0264261-8k_nektar.htm |
| 2025-09-18 | 8-K | ea0257842-8k_nektar.htm |
| 2025-08-08 | S-8 | ea0252127-s8_nektarthera.htm |
| Ms. Elizabeth Zhang |
| VP of Legal & Corporate Counsel |
| Ms. Jennifer Ruddock | Chief Business Officer |
| Ms. Sandra A. Gardiner | Interim Chief Financial Officer |